167 related articles for article (PubMed ID: 25894377)
1. Akt2/ZEB2 may be a biomarker for exfoliant cells in ascitic fluid in advanced grades of serous ovarian carcinoma.
Liu C; Yang F
Tumour Biol; 2015 Sep; 36(9):7213-9. PubMed ID: 25894377
[TBL] [Abstract][Full Text] [Related]
2. Recurrent BCAM-AKT2 fusion gene leads to a constitutively activated AKT2 fusion kinase in high-grade serous ovarian carcinoma.
Kannan K; Coarfa C; Chao PW; Luo L; Wang Y; Brinegar AE; Hawkins SM; Milosavljevic A; Matzuk MM; Yen L
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1272-7. PubMed ID: 25733895
[TBL] [Abstract][Full Text] [Related]
3. Role and prognostic significance of the epithelial-mesenchymal transition factor ZEB2 in ovarian cancer.
Prislei S; Martinelli E; Zannoni GF; Petrillo M; Filippetti F; Mariani M; Mozzetti S; Raspaglio G; Scambia G; Ferlini C
Oncotarget; 2015 Aug; 6(22):18966-79. PubMed ID: 26136338
[TBL] [Abstract][Full Text] [Related]
4. A FXYD5/TGF‑β/SMAD positive feedback loop drives epithelial‑to‑mesenchymal transition and promotes tumor growth and metastasis in ovarian cancer.
Bai Y; Li LD; Li J; Chen RF; Yu HL; Sun HF; Wang JY; Lu X
Int J Oncol; 2020 Jan; 56(1):301-314. PubMed ID: 31746425
[TBL] [Abstract][Full Text] [Related]
5. Delta-like 1 homologue promotes tumorigenesis and epithelial-mesenchymal transition of ovarian high-grade serous carcinoma through activation of Notch signaling.
Huang CC; Cheng SH; Wu CH; Li WY; Wang JS; Kung ML; Chu TH; Huang ST; Feng CT; Huang SC; Tai MH
Oncogene; 2019 Apr; 38(17):3201-3215. PubMed ID: 30626939
[TBL] [Abstract][Full Text] [Related]
6. Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma.
Bunkholt Elstrand M; Dong HP; Ødegaard E; Holth A; Elloul S; Reich R; Tropé CG; Davidson B
Hum Pathol; 2010 Jun; 41(6):794-804. PubMed ID: 20153512
[TBL] [Abstract][Full Text] [Related]
7. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.
Elloul S; Elstrand MB; Nesland JM; Tropé CG; Kvalheim G; Goldberg I; Reich R; Davidson B
Cancer; 2005 Apr; 103(8):1631-43. PubMed ID: 15742334
[TBL] [Abstract][Full Text] [Related]
8. ZEB2 facilitates peritoneal metastasis by regulating the invasiveness and tumorigenesis of cancer stem-like cells in high-grade serous ovarian cancers.
Li Y; Fei H; Lin Q; Liang F; You Y; Li M; Wu M; Qu Y; Li P; Yuan Y; Chen T; Jiang H
Oncogene; 2021 Aug; 40(32):5131-5141. PubMed ID: 34211089
[TBL] [Abstract][Full Text] [Related]
9. Ubiquitin-Proteasome Axis, Especially Ubiquitin-Specific Protease-17 (
Yildirim N; Kocal GC; Isik Z; Saatli B; Saygili U; Uysal T; Ulukus C; Koyuncuoglu M; Ellidokuz H; Basbinar Y
Reprod Sci; 2019 Jun; 26(6):794-805. PubMed ID: 30198418
[TBL] [Abstract][Full Text] [Related]
10. THE PROGNOSTIC SIGNIFICANCE OF P53, BCL2 AND MIB1 EXPRESSIONS RELATED WITH OTHER CLINICOPATHOLOGICAL VARIABLES IN SEROUS OVARIAN CARCINOMAS. A CLINICOPATHOLOGICAL STUDY IN PERITONEAL FLUIDS.
Kalogeraki A; Tamiolakis D; Matalliotaki C; Karvela-Kalogeraki I; Karvelas-Kalogerakis M; Segredakis J; Sinatkas V; Matalliotakis I
Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):454-60. PubMed ID: 26204652
[TBL] [Abstract][Full Text] [Related]
11. MiR-338-3p inhibits epithelial-mesenchymal transition in gastric cancer cells by targeting ZEB2 and MACC1/Met/Akt signaling.
Huang N; Wu Z; Lin L; Zhou M; Wang L; Ma H; Xia J; Bin J; Liao Y; Liao W
Oncotarget; 2015 Jun; 6(17):15222-34. PubMed ID: 25945841
[TBL] [Abstract][Full Text] [Related]
12. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival.
Davidson B; Trope' CG; Wang TL; Shih IeM
Gynecol Oncol; 2006 Dec; 103(3):814-9. PubMed ID: 16844205
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer.
Elattar A; Warburton KG; Mukhopadhyay A; Freer RM; Shaheen F; Cross P; Plummer ER; Robson CN; Edmondson RJ
Gynecol Oncol; 2012 Jan; 124(1):142-7. PubMed ID: 22001143
[TBL] [Abstract][Full Text] [Related]
14. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D
Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008
[TBL] [Abstract][Full Text] [Related]
15. CLIC1 a novel biomarker of intraperitoneal metastasis in serous epithelial ovarian cancer.
Ye Y; Yin M; Huang B; Wang Y; Li X; Lou G
Tumour Biol; 2015 Jun; 36(6):4175-9. PubMed ID: 25582317
[TBL] [Abstract][Full Text] [Related]
16. Putative stem cells and epithelial-mesenchymal transition revealed in sections of ovarian tumor in patients with serous ovarian carcinoma using immunohistochemistry for vimentin and pluripotency-related markers.
Kenda Suster N; Smrkolj S; Virant-Klun I
J Ovarian Res; 2017 Feb; 10(1):11. PubMed ID: 28231820
[TBL] [Abstract][Full Text] [Related]
17. Ezrin Is Associated with Disease Progression in Ovarian Carcinoma.
Horwitz V; Davidson B; Stern D; Tropé CG; Tavor Re'em T; Reich R
PLoS One; 2016; 11(9):e0162502. PubMed ID: 27622508
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II type 2 receptor-interacting protein 3a inhibits ovarian carcinoma metastasis via the extracellular HMGA2-mediated ERK/EMT pathway.
Ping H; Guo L; Xi J; Wang D
Tumour Biol; 2017 Jun; 39(6):1010428317713389. PubMed ID: 28651497
[TBL] [Abstract][Full Text] [Related]
19. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions.
Davidson B; Holth A; Hellesylt E; Tan TZ; Huang RY; Tropé C; Nesland JM; Thiery JP
Hum Pathol; 2015 Jan; 46(1):1-8. PubMed ID: 25455994
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-153 functions as a tumor suppressor by targeting SET7 and ZEB2 in ovarian cancer cells.
Zhou J; Xie M; Shi Y; Luo B; Gong G; Li J; Wang J; Zhao W; Zi Y; Wu X; Wen J
Oncol Rep; 2015 Jul; 34(1):111-20. PubMed ID: 25954928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]